Skip to main content

Advertisement

Table 3 Subgroup analysis of changes in SDAI values and circulating biomarkers following 6 months DMARD, for the methotrexate (MTX) monotherapy and methotrexate- prednisone combination therapy groups

From: Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis

Variable n Baseline 6 months P value
MTX only Median IQR Median IQR
SDAI 43 33.58 24.75 16.03 11.05 0.0001
CRP (μg/ml) 43 9.90 21.30 6.90 13.40 0.0048
ACPA (IU/ml) 36 501.60 844.50 310.90 559.60 0.0033
IL-7 (pg/ml) 42 14.78 64.04 14.17 19.73 NS
IL-8 (pg/ml) 42 7.68 8.84 5.01 5.32 0.0091
IL-10 (pg/ml) 7 6.68 48.16 8.41 23.41 NS
VEGF (pg/ml) 42 114.16 240.82 97.52 184.54 NS
Variable n Baseline 6 months P value
MTX PRED Median IQR Median IQR
SDAI 33 38.90 20.64 18.00 18.73 0.0001
CRP (μg/ml) 33 35.90 36.50 11.60 19.10 0.0005
ACPA (IU/ml) 29 598.90 1036.60 367.20 699.50 0.0001
IL-7 (pg/ml) 28 46.67 161.13 21.46 31.06 0.0026
IL-8 (pg/ml) 28 10.35 13.27 5.84 4.03 0.0002
IL-10 (pg/ml) 14 12.99 18.55 8.50 23.95 0.048
VEGF (pg/ml) 28 318.91 482.44 77.08 159.38 0.0044